How much profit has Chiome Bioscience made this year?
Chiome Bioscience has made -1.22 B JPY this year.
Chiome Bioscience Net Income 2024
Chiome Bioscience Net Income
-1.22 B JPY
Ticker
4583.T
ISIN
JP3205350006
In 2024, Chiome Bioscience's profit amounted to -1.22 B JPY, a -1.84% increase from the -1.24 B JPY profit recorded in the previous year.
The Chiome Bioscience Net Income history
| YEAR | NET INCOME (undefined JPY) |
|---|---|
| 2023 | - |
| 2022 | - |
| 2021 | - |
| 2020 | - |
| 2019 | - |
| 2018 | - |
| 2017 | - |
| 2016 | - |
| 2015 | - |
| 2014 | - |
| 2013 | - |
| 2012 | - |
| 2011 | - |
| 2010 | - |
| 2009 | - |
| 2008 | - |
| 2007 | - |
| 2006 | - |
Chiome Bioscience Revenue, EBIT, Net Income JP3205350006 ·
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Chiome Bioscience, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Chiome Bioscience from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Chiome Bioscience’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Chiome Bioscience. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Chiome Bioscience’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Chiome Bioscience’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Chiome Bioscience’s growth potential.
Chiome Bioscience Revenue, EBIT and net profit per share
| Date | Chiome Bioscience Revenue | Chiome Bioscience EBIT | Chiome Bioscience Net Income |
|---|---|---|---|
| 2023 | 682.46 M undefined | -1.21 B undefined | -1.22 B undefined |
| 2022 | 630.82 M undefined | -1.26 B undefined | -1.24 B undefined |
| 2021 | 712.93 M undefined | -1.33 B undefined | -1.48 B undefined |
| 2020 | 480.85 M undefined | -1.28 B undefined | -1.29 B undefined |
| 2019 | 447.58 M undefined | -1.4 B undefined | -1.4 B undefined |
| 2018 | 212.85 M undefined | -1.54 B undefined | -1.53 B undefined |
| 2017 | 259.9 M undefined | -887.87 M undefined | -882.57 M undefined |
| 2016 | 252.22 M undefined | -1.04 B undefined | -1.49 B undefined |
| 2015 | 280.11 M undefined | -1.27 B undefined | -1.28 B undefined |
| 2014 | 277.8 M undefined | -865.6 M undefined | -863.3 M undefined |
| 2013 | 435 M undefined | -708.9 M undefined | -757.6 M undefined |
| 2012 | 324.1 M undefined | -413.2 M undefined | -426.9 M undefined |
| 2011 | 633.2 M undefined | -7.3 M undefined | -44.4 M undefined |
| 2010 | 463.2 M undefined | -231.2 M undefined | -180.2 M undefined |
| 2009 | 380.8 M undefined | -201.5 M undefined | -164.4 M undefined |
| 2008 | 161.8 M undefined | -213 M undefined | -204.6 M undefined |
| 2007 | 34.2 M undefined | -248.9 M undefined | -227.3 M undefined |
| 2006 | 13.9 M undefined | -193.8 M undefined | -141.9 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2006 | 13.9 M JPY | -193.8 M JPY | -141.9 M JPY |
| 2007 | 34.2 M JPY | -248.9 M JPY | -227.3 M JPY |
| 2008 | 161.8 M JPY | -213 M JPY | -204.6 M JPY |
| 2009 | 380.8 M JPY | -201.5 M JPY | -164.4 M JPY |
| 2010 | 463.2 M JPY | -231.2 M JPY | -180.2 M JPY |
| 2011 | 633.2 M JPY | -7.3 M JPY | -44.4 M JPY |
| 2012 | 324.1 M JPY | -413.2 M JPY | -426.9 M JPY |
| 2013 | 435 M JPY | -708.9 M JPY | -757.6 M JPY |
| 2014 | 277.8 M JPY | -865.6 M JPY | -863.3 M JPY |
| 2015 | 280.11 M JPY | -1.27 B JPY | -1.28 B JPY |
| 2016 | 252.22 M JPY | -1.04 B JPY | -1.49 B JPY |
| 2017 | 259.9 M JPY | -887.87 M JPY | -882.57 M JPY |
| 2018 | 212.85 M JPY | -1.54 B JPY | -1.53 B JPY |
| 2019 | 447.58 M JPY | -1.4 B JPY | -1.4 B JPY |
| 2020 | 480.85 M JPY | -1.28 B JPY | -1.29 B JPY |
| 2021 | 712.93 M JPY | -1.33 B JPY | -1.48 B JPY |
| 2022 | 630.82 M JPY | -1.26 B JPY | -1.24 B JPY |
| 2023 | 682.46 M JPY | -1.21 B JPY | -1.22 B JPY |
Chiome Bioscience stock margins JP3205350006 ·
The Chiome Bioscience margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Chiome Bioscience. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Chiome Bioscience.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Chiome Bioscience's sales revenue. A higher gross margin percentage indicates that the Chiome Bioscience retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Chiome Bioscience's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Chiome Bioscience's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Chiome Bioscience's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Chiome Bioscience. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Chiome Bioscience's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Chiome Bioscience Margin History
| Chiome Bioscience Gross margin | Chiome Bioscience Profit margin | Chiome Bioscience EBIT margin | Chiome Bioscience Profit margin |
|---|---|---|---|
| 2023 | 58.41 % | -176.59 % | -178.77 % |
| 2022 | 55.3 % | -199.53 % | -197.03 % |
| 2021 | 59.26 % | -187.16 % | -207.58 % |
| 2020 | 51.01 % | -266.95 % | -269.06 % |
| 2019 | 63.6 % | -313.23 % | -313.65 % |
| 2018 | 52.28 % | -723.1 % | -720.46 % |
| 2017 | 67.11 % | -341.63 % | -339.59 % |
| 2016 | 45.36 % | -413.28 % | -591.23 % |
| 2015 | 50.71 % | -453.36 % | -457.93 % |
| 2014 | 67.93 % | -311.59 % | -310.76 % |
| 2013 | 60 % | -162.97 % | -174.16 % |
| 2012 | 63.16 % | -127.49 % | -131.72 % |
| 2011 | 66.3 % | -1.15 % | -7.01 % |
| 2010 | 57.08 % | -49.91 % | -38.9 % |
| 2009 | 57.43 % | -52.91 % | -43.17 % |
| 2008 | 42.09 % | -131.64 % | -126.45 % |
| 2007 | 36.84 % | -727.78 % | -664.62 % |
| 2006 | 33.81 % | -1,394.24 % | -1,020.86 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2006 | 33.81 % | -1,394.24 % | -1,020.86 % |
| 2007 | 36.84 % | -727.78 % | -664.62 % |
| 2008 | 42.09 % | -131.64 % | -126.45 % |
| 2009 | 57.43 % | -52.91 % | -43.17 % |
| 2010 | 57.08 % | -49.91 % | -38.9 % |
| 2011 | 66.3 % | -1.15 % | -7.01 % |
| 2012 | 63.16 % | -127.49 % | -131.72 % |
| 2013 | 60 % | -162.97 % | -174.16 % |
| 2014 | 67.93 % | -311.59 % | -310.76 % |
| 2015 | 50.71 % | -453.36 % | -457.93 % |
| 2016 | 45.36 % | -413.28 % | -591.23 % |
| 2017 | 67.11 % | -341.63 % | -339.59 % |
| 2018 | 52.28 % | -723.1 % | -720.46 % |
| 2019 | 63.6 % | -313.23 % | -313.65 % |
| 2020 | 51.01 % | -266.95 % | -269.06 % |
| 2021 | 59.26 % | -187.16 % | -207.58 % |
| 2022 | 55.3 % | -199.53 % | -197.03 % |
| 2023 | 58.41 % | -176.59 % | -178.77 % |
Chiome Bioscience Aktienanalyse
What does Chiome Bioscience do?
Chiome Bioscience ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Chiome Bioscience's Profit Margins
The profit margins of Chiome Bioscience represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Chiome Bioscience's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Chiome Bioscience's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Chiome Bioscience's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Chiome Bioscience’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Chiome Bioscience stock
How has the profit developed compared to last year?
The profit has increased by -1.84% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Chiome Bioscience publish its earnings?
Chiome Bioscience publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Chiome Bioscience?
The profits of Chiome Bioscience are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Chiome Bioscience?
You can learn more about the earnings of Chiome Bioscience by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Chiome Bioscience pay?
Over the past 12 months, Chiome Bioscience paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Chiome Bioscience is expected to pay a dividend of 0 JPY.
What is the dividend yield of Chiome Bioscience?
The current dividend yield of Chiome Bioscience is .
When does Chiome Bioscience pay dividends?
Chiome Bioscience pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Chiome Bioscience?
Chiome Bioscience paid dividends every year for the past 0 years.
What is the dividend of Chiome Bioscience?
For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.
In which sector is Chiome Bioscience located?
Chiome Bioscience is assigned to the 'Health' sector.
Wann musste ich die Aktien von Chiome Bioscience kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Chiome Bioscience from 8/28/2024 amounting to 0 JPY, you needed to have the stock in your portfolio before the ex-date on 8/28/2024.
When did Chiome Bioscience pay the last dividend?
The last dividend was paid out on 8/28/2024.
What was the dividend of Chiome Bioscience in the year 2023?
In the year 2023, Chiome Bioscience distributed 0 JPY as dividends.
In which currency does Chiome Bioscience pay out the dividend?
The dividends of Chiome Bioscience are distributed in JPY.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Chiome Bioscience
Our stock analysis for Chiome Bioscience Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Chiome Bioscience Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Chiome Bioscience Revenue
- Chiome Bioscience Net Income
- Chiome Bioscience P/E
- Chiome Bioscience P/S
- Chiome Bioscience EBIT
- Chiome Bioscience Dividend
- Chiome Bioscience Stocks
- Chiome Bioscience Market capitalization
- Chiome Bioscience Debt
- Chiome Bioscience Liabilities
- Chiome Bioscience Equity
- Chiome Bioscience AAQS
- Chiome Bioscience Employees
- Chiome Bioscience ROE
- Chiome Bioscience ROA
- Chiome Bioscience ROCE